| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
trans-Zeatin-d5 does not have a specific pharmacological target in mammalian systems. trans-Zeatin is a plant cytokinin that plays important roles in cell growth, differentiation, and division. It has been shown to inhibit UV-induced MEK/ERK activation. The deuterated form is used as an internal standard for analytical quantification.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
trans-Zeatin-d5 is used in vitro as a tracer to study cytokinin metabolism and signaling in plant cells. The compound does not exhibit intrinsic pharmacological activity in mammalian systems but serves as a quantitative tool for studying plant hormone biology. In mammalian cell studies, it can be used to track the effects of trans-Zeatin on MEK/ERK signaling. |
| ln Vivo |
In vivo, trans-Zeatin-d5 is used in metabolic studies to trace the absorption, distribution, metabolism, and excretion of trans-Zeatin in plant and animal systems. The deuterium label allows for precise quantification of the compound and its metabolites using mass spectrometry.
|
| Enzyme Assay |
As an internal standard, trans-Zeatin-d5 is specifically designed for use in GC-MS and LC-MS/MS applications. Typical protocols involve spiking the labeled compound into samples prior to extraction and analysis. The compound serves as an internal standard to correct for matrix effects and instrument variability.
|
| Cell Assay |
In vitro cell culture experiments using trans-Zeatin-d5 involve treating plant or mammalian cells with the labeled compound and analyzing its uptake and metabolism by mass spectrometry. The compound can be used to study cytokinin signaling and the effects of trans-Zeatin on cell growth and differentiation.
|
| Animal Protocol |
In vivo animal studies using trans-Zeatin-d5 involve administering the compound to rodents via oral gavage or intravenous injection. Blood samples are collected at various time points, and the concentration of the labeled compound is measured by mass spectrometry.
|
| ADME/Pharmacokinetics |
trans-Zeatin-d5 exhibits pharmacokinetic properties similar to those of unlabeled trans-Zeatin. As a plant hormone, it is metabolized by plant-specific enzymes. In mammalian systems, it is rapidly metabolized and excreted. The deuterium label provides a distinct mass shift for analytical detection.
|
| Toxicity/Toxicokinetics |
trans-Zeatin-d5 is considered safe for research use at typical concentrations. As a plant hormone, it has low toxicity in mammalian systems. The compound is stable under recommended storage conditions. As a stable isotope-labeled compound, it is not intended for therapeutic use and is handled under standard laboratory safety practices.
|
| References |
|
| Additional Infomation |
trans-Zeatin-d5 has a molecular formula of C₁₀H₈D₅N₅O and a molecular weight of 224.27. The compound is a stable isotope-labeled internal standard (SIL-IS) specifically designed for analytical applications. It is primarily used in GC-MS and LC-MS/MS applications for the quantification of trans-Zeatin in biological matrices.
|
| Molecular Formula |
C10H8D5N5O
|
|---|---|
| Molecular Weight |
0
|
| Exact Mass |
224.143
|
| CAS # |
72963-19-0
|
| Related CAS # |
trans-Zeatin;1637-39-4
|
| PubChem CID |
131884164
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
16
|
| Complexity |
258
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])/C(=C\CNC1=NC=NC2=C1NC=N2)/C([2H])([2H])O
|
| InChi Key |
UZKQTCBAMSWPJD-NZHOCFFMSA-N
|
| InChi Code |
InChI=1S/C10H13N5O/c1-7(4-16)2-3-11-9-8-10(13-5-12-8)15-6-14-9/h2,5-6,16H,3-4H2,1H3,(H2,11,12,13,14,15)/b7-2+/i1D3,4D2
|
| Chemical Name |
(E)-1,1-dideuterio-4-(7H-purin-6-ylamino)-2-(trideuteriomethyl)but-2-en-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
